Drug Profile
GS 5759
Alternative Names: GS-5759Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Anti-inflammatories; Bronchodilators; Quinolines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation) (Gilead Sciences pipeline, October 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 15 Feb 2017 Chemical structure information added